Celgene has finalised the purchase of US-based biopharmaceutical firm Juno Therapeutics for approximately $9bn, amounting to $87 per share.
The companies signed a definitive merger agreement in January 2018 intended to boost Celgene’s position in the haematology market and provide required support for the growth of Juno.
The deal will advance Celgene’s cellular manufacturing capabilities and add new technologies to its portfolio, putting it at the forefront of the cellular immunotherapy market.
Celgene chairman and CEO of Mark Alles said: “Our colleagues at Juno are developing some of the most promising approaches to treating cancer, and we are excited to add their pioneering work to Celgene’s leading haematology and oncology research and commercial platform.
“Together, we expect to expand our opportunities to discover and develop new therapies that will improve and extend the lives of patients worldwide.”
The acquisition will expand Celgene’s lymphoma programme by providing complete global rights to Juno’s CD-19 targeted CAR T therapy, JCAR017 (lisocabtagene maraleucel; liso-cel).
The CAR T drug candidate is being developed to treat relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) and is expected to gain US regulatory approval in 2019.
JCAR017 is expected to be a growth driver from 2020, bringing in global peak sales of about $3bn.
Celgene also plans to use Juno’s research and development facility in Seattle and its manufacturing facility in Bothell, Washington to expand its existing centre of excellence for immuno-oncology translational medicine.